Search Results - "Mina, L.A."

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial by Litton, J.K., Hurvitz, S.A., Mina, L.A., Rugo, H.S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., Roché, H., Im, Y.-H., Eiermann, W., Quek, R.G.W., Usari, T., Lanzalone, S., Czibere, A., Blum, J.L., Martin, M., Ettl, J.

“…In EMBRACA, talazoparib prolonged progression-free survival versus chemotherapy (hazard ratio [HR] 0.542 [95% confidence interval (CI) 0.413-0.711]; P <…”
Get full text

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial by Ettl, J., Quek, R.G.W., Lee, K.-H., Rugo, H.S., Hurvitz, S., Gonçalves, A., Fehrenbacher, L., Yerushalmi, R., Mina, L.A., Martin, M., Roché, H., Im, Y.-H., Markova, D., Bhattacharyya, H., Hannah, A.L., Eiermann, W., Blum, J.L., Litton, J.K.

“…In the EMBRACA phase III trial, talazoparib (1mg daily, orally) demonstrated a statistically significant improvement in PFS versus physician’s choice of…”
Get full text

Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations by Turner, N.C., Laird, A.D., Telli, M.L., Rugo, H.S., Mailliez, A., Ettl, J., Grischke, E.-M., Mina, L.A., Balmaña, J., Fasching, P.A., Hurvitz, S.A., Albacker, L.A., Frampton, G.M., Chelliserry, J., Bycott, P., Conte, U., Wardley, A.M., Robson, M.E.

Get full text

314P - Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations by Turner, N.C., Laird, A.D., Telli, M.L., Rugo, H.S., Mailliez, A., Ettl, J., Grischke, E.-M., Mina, L.A., Balmaña, J., Fasching, P.A., Hurvitz, S.A., Albacker, L.A., Frampton, G.M., Chelliserry, J., Bycott, P., Conte, U., Wardley, A.M., Robson, M.E.

“…Loss-of-function mutations in genes encoding components of the homologous recombination (HR) machinery are associated with tumor sensitivity to poly…”
Get full text

Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial by Hurvitz, S.A., Quek, R.G.W., Turner, N.C., Telli, M.L., Rugo, H.S., Mailliez, A., Ettl, J., Grischke, E., Mina, L.A., Balmaña, J., Fasching, P.A., Bhattacharyya, H., Hannah, A.L., Robson, M.E., Wardley, A.M.

“…Talazoparib (1 mg/day) exhibited promising efficacy and safety in patients with advanced breast cancer during ABRAZO (NCT02034916); this study evaluated…”
Get full text